Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,654
  • Shares Outstanding, K 44,405
  • Annual Sales, $ 380 K
  • Annual Income, $ -51,260 K
  • 60-Month Beta 2.02
  • Price/Sales 77.56
  • Price/Cash Flow N/A
  • Price/Book 7.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5603 +77.58%
on 09/24/20
1.0100 -1.49%
on 09/29/20
+0.1250 (+14.37%)
since 08/28/20
3-Month
0.5603 +77.58%
on 09/24/20
1.3000 -23.46%
on 07/30/20
-0.0450 (-4.33%)
since 06/29/20
52-Week
0.4195 +137.19%
on 04/02/20
1.7050 -41.64%
on 12/18/19
+0.0451 (+4.75%)
since 09/27/19

Most Recent Stories

More News
Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,...

SEEL : 1.0500 (+34.62%)
Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced...

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced...

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct Offering

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has closed its previously announced registered direct offering to certain...

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics Announces Pricing of $7.0 Million Registered Direct Offering

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase agreement with certain institutional...

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,...

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,...

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,

SEEL : 1.0500 (+34.62%)
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,...

SEEL : 1.0500 (+34.62%)
Thinking about buying stock in Trevena, Translate Bio, Workhorse Group, Dynavax Technologies, or Seelos Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, TBIO, WKHS, DVAX, and SEEL.

SEEL : 1.0500 (+34.62%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade SEEL with:

Business Summary

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which...

See More

Key Turning Points

2nd Resistance Point 1.0634
1st Resistance Point 0.9219
Last Price 1.0500
1st Support Level 0.6395
2nd Support Level 0.4986

See More

52-Week High 1.7050
Fibonacci 61.8% 1.2139
Fibonacci 50% 1.0623
Last Price 1.0500
Fibonacci 38.2% 0.9106
52-Week Low 0.4195

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar